Actively Recruiting
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
Led by Medical University of South Carolina · Updated on 2026-05-06
172
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Participants will be randomly assigned to receive either DSLT or SLT and followed for 12 months to assess eye pressure, safety, and treatment outcomes.
CONDITIONS
Official Title
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of open-angle glaucoma (including exfoliative or pigmentary types) or ocular hypertension
- Open angle confirmed by gonioscopy with visible scleral spur 360 degrees
- Ability to provide consent and comply with study follow-up visits
You will not qualify if you...
- Presence of angle-closure or secondary glaucomas
- Intraocular pressure greater than 35 mmHg despite therapy
- Corneal disease that interferes with laser treatment or eye pressure measurement
- Eye surgery within the past 6 months
- Contraindications to study medications or procedures
- Cognitive impairment that prevents giving informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MUSC
Charleston, South Carolina, United States, 29407
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here